$295 M

SBTX Mkt cap, 12-Nov-2021
Silverback Therapeutics Net income (Q1, 2021)-18.9 M
Silverback Therapeutics EBIT (Q1, 2021)-18.9 M
Silverback Therapeutics Cash, 31-Mar-2021374.2 M
Silverback Therapeutics EV-76.2 M
Get notified regarding key financial metrics and revenue changes at Silverback TherapeuticsLearn more
Banner background

Silverback Therapeutics Income Statement

Annual

USDFY, 2018FY, 2019

R&D expense

14.8m21.5m

General and administrative expense

3.5m2.6m

Operating expense total

18.3m24.1m

EBIT

(18.3m)(24.1m)

Interest income

43.0k100.0k

Net Income

(17.6m)(24.0m)

EPS

(29.1)(36.3)

Quarterly

USDQ1, 2021

R&D expense

12.2m

General and administrative expense

6.6m

Operating expense total

18.9m

EBIT

(18.9m)

Interest expense

18.0k

Net Income

(18.9m)

Silverback Therapeutics Balance Sheet

Annual

USDFY, 2018FY, 2019

Cash

20.2m10.0m

Current Assets

20.8m10.5m

PP&E

1.8m1.3m

Total Assets

27.5m15.6m

Accounts Payable

775.0k3.5m

Short-term debt

3.5m2.3m

Current Liabilities

5.1m17.9m

Long-term debt

4.2m3.3m

Total Debt

7.7m5.6m

Total Liabilities

9.4m21.3m

Preferred Stock

53.2m53.2m

Additional Paid-in Capital

4.8m5.0m

Retained Earnings

(39.8m)(63.8m)

Total Equity

(35.0m)(58.8m)

Debt to Equity Ratio

-0.2 x-0.1 x

Debt to Assets Ratio

0.3 x0.4 x

Financial Leverage

-0.8 x-0.3 x

Quarterly

USDQ3, 2020Q1, 2021

Cash

142.3m374.2m

Prepaid Expenses

4.1m

Current Assets

143.2m378.3m

PP&E

1.7m1.6m

Total Assets

148.9m382.2m

Accounts Payable

2.2m4.4m

Short-term debt

1.9m927.0k

Current Liabilities

8.0m11.6m

Long-term debt

2.6m2.1m

Total Debt

4.5m3.0m

Total Liabilities

10.6m13.7m

Common Stock

3.0k

Preferred Stock

216.6m

Additional Paid-in Capital

5.4m484.1m

Retained Earnings

(83.6m)(115.6m)

Total Equity

(78.2m)368.5m

Debt to Equity Ratio

-0.1 x

Debt to Assets Ratio

0 x

Financial Leverage

-1.9 x1 x

Silverback Therapeutics Cash Flow

Annual

USDFY, 2018FY, 2019

Net Income

(17.6m)(24.0m)

Depreciation and Amortization

480.0k544.0k

Accounts Payable

513.0k4.0m

Cash From Operating Activities

(16.9m)(18.9m)

Purchases of PP&E

(449.0k)(96.0k)

Cash From Investing Activities

(449.0k)(96.0k)

Short-term Borrowings

(852.0k)(1.4m)

Cash From Financing Activities

19.4m8.6m

Net Change in Cash

2.1m(10.4m)

Interest Paid

58.0k36.0k

Quarterly

USDQ3, 2019Q3, 2020Q1, 2021

Net Income

(17.0m)(19.9m)(18.9m)

Depreciation and Amortization

406.0k448.0k186.0k

Accounts Payable

3.5m(914.0k)2.2m

Cash From Operating Activities

(13.0m)(20.1m)(12.2m)

Purchases of PP&E

(96.0k)(670.0k)(35.0k)

Cash From Investing Activities

(96.0k)(670.0k)(35.0k)

Short-term Borrowings

(1.0m)(467.0k)(350.0k)

Cash From Financing Activities

(1.0m)153.1m(128.0k)

Net Change in Cash

(14.1m)132.3m(12.4m)

Interest Paid

30.0k13.0k

Silverback Therapeutics Ratios

USDFY, 2018

Debt/Equity

-0.2 x

Debt/Assets

0.3 x

Financial Leverage

-0.8 x

Silverback Therapeutics Operating Metrics

Q3, 2020

Lead Optimization Stage Products

1

IND-Enabling Stage Products

1

Phase I Trials Products

1